

02-28-06

ITW

Attorney's Docket No. 046562/274659

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Fraser *et al.* Confirmation No.: 4482
Appl. No.: 10/769,952 Group Art Unit: 1614
Filed: March 10, 2004 Examiner: Satyanarayana R.
Gudibande
For: METHODS FOR TREATING LOWER URINARY TRACT DISORDERS AND
THE RELATED DISORDERS VULVODYNIA AND VULVAR
VESTIBULITIS USING CAV2.2 SUBUNIT CALCIUM CHANNEL
MODULATORS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

February 27, 2006

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
CITATION UNDER 37 C.F.R. § 1.97**

Sir:

The present Supplemental Information Disclosure Statement is filed in response to the Office Action dated August 30, 2005 for U.S. Patent Application No. 10/769,952. In that Office Action, the Examiner states that several references cited in the Information Disclosure Statement of September 16, 2004 were not considered because copies of those references were not received. The references not considered by the Examiner are listed in the attached form PTO-1449, copies of which are enclosed in accordance with 37 CFR 1.98(a)(2).


It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.


Applicants note that EP 1 117 680 and EP 1 042 468 have been replaced by their corresponding PCT application publications under Article 158 EPC. Accordingly, copies of WO 00/18801 (corresponding to EP 1 117 680) and WO 99/28342 (corresponding to EP 1 042 468)

In re: Fraser et al.
Appl. No.: 10/769,952
Filed: March 10, 2004
Page 2

have been provided. Applicants also note that an English language abstract has been provided for JP 11035483. It is Applicants' intent that this English language abstract serve as a concise explanation of the relevance of JP 11035483 in accordance with 37 CFR 1.98(a)(3)(i).

Respectfully submitted,


Edward R. Ergenzinger
Registration No. 47,549

CUSTOMER NO. 00826 ALSTON & BIRD LLP Bank of America Plaza 101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000 Tel Raleigh Office (919) 862-2200 Fax Raleigh Office (919) 862-2260	"Express Mail" mailing label number EV 387075042 US Date of Deposit February 27, 2006 I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450  Lynda Jo Pixley
--	---

Substitute for form 1449/PTO
(Revised 04/2003)

Complete if Known

Application Number	10/769,958
Filing Date	March 10, 2004
First Named Inventor	Fraser
Group Art Unit	1614
Examiner Name	Not yet assigned
Attorney Docket Number	046562/274659

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
	1	WO 98/23639	06-04-1998	University of Florida et al.		
	2	JP 11035483	02-19-1999	Nippon Kayaku Co. Ltd.		Abstract Only
	3	EP 1 042 468 A2 (WO 99/28342)	10-11-2000	Mark et al.		
	4	EP 1 117 680 A2 (WO 00/18801)	07-25-2001	Ronn et al.		
	5	WO 03/018561 A1	03-06-2003	Astrazeneca AB		
	6	WO 2004/054560 A1	07-01-2004	Warner-Lambert Company LLC		

OTHER DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) , volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	7	MAGGI, C.A., <i>et al.</i> , "Effect of Omega Conotoxin on Reflex Responses Mediated by Activation of Capsaicin-Sensitive Nerves of the Rat Urinary Bladder and Peptide Release from the Rat Spinal Cord," <i>Neuroscience</i> , 1990, pp. 243-250, vol. 34(1).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.